The interest in psychedelics for health-related purposes has grown significantly over the past decade. However, there is an insufficient representation of stakeholders (eg, Indigenous groups, activists, policymakers) in discussions about research and regulation. Many psychedelics originate from traditional practices historically developed in low- and middle-...
Psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are psychedelic compounds with therapeutic potential for depression, anxiety, and post-traumatic stress. However, their relevance to endurance athletes, who face particular psychological and physical stressors, remains underexplored. This ...
ABSTRACT This paper examines the intimate relationship of affection, consumption, and ritual practice between humanity and mushrooms of the genus Psilocybe, focusing mainly on the Americas and Brazil. To this end, it uses reflections that present the American continent as a macroregion historically marked by transits, connections, and exchanges since pre-Col...
Psilocybin is a molecule with significant potential for the treatment of mental disorders such as depression, anxiety, post-traumatic stress disorder, and substance abuse. In this study, it was explored the extraction of psilocybin from Psilocybe cubensis mushrooms using a factorial design approach, along with the physicochemical and phytochemical characteri...
Current drug policy classifies psilocybin, a compound found in psychoactive mushrooms, as having high abuse potential while overlooking its therapeutic properties. We evaluated the risk of psilocybin mushrooms to Brazilian public health compared to other toxic agents and assessed the need for regulatory discussions. This retrospective cross-sectional study f...
Various families of mushrooms contain important phytochemicals with significant potential. This study aimed to investigate the phytochemical prospecting, presence of psilocybin, antioxidant activities, and acetylcholinesterase inhibition in aqueous extracts of Cyathus striatus, Laternea dringii, and Marasmius haematocephalus. Aqueous extracts were produced f...
Psilocybin and psilocin do not cause addiction or dependence, as they do not interact with the dopaminergic reward system. New pharmacological treatment strategies for substance abuse disorders have targeted craving, which is characterized, in a simplified way, by an intense desire to use the substance. Psilocybin is an indole alkaloid of the hallucinogenic ...
Background Current drug policy classifies psilocybin, a substance produced by psychoactive mushrooms, as having a high potential for abuse, neglecting its therapeutic properties. We aimed to investigate if psilocybin mushrooms pose a risk to Brazilian public health compared to other toxic agents and whether evidence-based regulatory discussions are needed. M...
Psilocin is the active metabolite of psilocybin a natural material found in several types of fungi. The bioavailability of psilocybin, the prodrug of psilocin, has been reported to be over 60%. However, pharmacokinetics and bioavailability of psilocin mucate has not been reported. This Phase I "First in Man" study of psilocin mucate is designed to determine ...
Psychedelics were used in the treatment of psychiatric conditions prior to their prohibition in the late 1960s. In the past three decades, there is a revived research interest in the therapeutic potential of psychedelic drugs with expected FDA approvals for treatment of various conditions. Given the exponential scientific growth of this field, we sought to c...
This study sought to investigate the effects of different substances on nature relatedness (NR) in the general population. An online cross-sectional survey done in Brazil investigated use of ayahuasca/DMT, mushrooms, LSD, MDMA/ecstasy, cocaine, cannabis, and alcohol. NR was assessed using the short-form version of the nature related scale (NR-6). One-way ana...
Dados da Organização Mundial de Saúde (OMS) informam que a depressão circunda entre as doenças mais incapacitantes do mundo, estimando-se que mais de 300 milhões de pessoas sofram com esta patologia. A psilocibina é um princípio ativo extraído do cogumelo do gênero Psilocybe de natureza química semelhante ao neurotransmissor serotonina (5- hidroxitriptamina)...
Introdução: A depressão é um transtorno psiquiátrico caracterizado por episódios agudos ou recorrentes de humor deprimido e perda de interesse ou prazer, levando a prejuízos funcionais ao paciente. A psilocibina é uma droga psicodélica com propriedades alucinógenas e serotoninérgicas derivada de cogumelos do gênero Psilocybe. Estudos recentes demonstram pote...
